Dr Evans obtained a BSc in Exercise Sciences (1st class honours) at the University of Birmingham (2004-2006). He was then awarded a British Heart Foundation (BHF) Studentship to complete a PhD in Cardiovascular Medicine (pass without corrections) under the supervision of Prof Alberto Smith at King’s College London BHF Centre of Research Excellence (2007-2010). His postdoctoral training was carried out in the laboratory of Prof Randall Johnson at the University of California San Diego and subsequently at the University of Cambridge BHF Centre of Research Excellence (2011-2015).
Dr Evans was recently awarded a Parke Davis Fellowship by the University of Cambridge to continue his research as Visiting Scholar in the Center for Lung and Vascular Biology at the University of Illinois at Chicago (2016-2017). Colin is also a Junior Research Fellow of Wolfson College (University of Cambridge) and the Launch Editor of Hypoxia. He has received several grants and awards, including the 2012 Young International Investigator Award from the Australasian Society of Thrombosis and Haemostasis. Dr Evans’ sources of funding include the BHF, the British Society for Haematology, and Thrombosis UK.
Dr Evans studies mechanisms that regulate the associations between hypoxia, thrombosis, and other vascular diseases. Thrombi are more likely to form in cancer patients compared with healthy people, and blood flow to newly formed thrombi and tumours is restricted. Dr Evans is investigating whether hypoxia-inducible factors (HIFs) in cells within the tumour microenvironment stimulate thrombosis and, conversely, whether HIFs in cells within and around the thrombus stimulate tumour progression. A better understanding of the mechanisms that control thrombosis-associated cancer progression may lead to the development of novel treatments for patients with Trousseau's Syndrome (i.e. hypercoagulable malignancy).
Dr Evans’ research also aims to identify mechanisms that control thrombus formation and subsequent resolution, which could lead to the development of new therapies that reduce the incidence of deep vein thrombosis or the risk of pulmonary embolism. In related work, Colin is aiming to determine whether the vascular response to thrombosis-induced hypoxia regulates pulmonary function and hypercoagulation during sepsis.
Evans CE, Bendahl P-O, Belting M, Branco C, Johnson RS. Diverse roles of cell-specific HIF1 in cancer-associated hypercoagulation. Blood, 2016, 127(10), 1355-60.
Grover SP, Evans CE (joint first author), Patel AS, Modarai M, Saha P, Smith A. Assessment of venous thrombosis in animal models. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36(2), 245-52.
Evans CE, Grover SP, Jenkins J, Saha P, Patel A, Patel AS, Lyons OT, Modarai B, Smith A. Anti-angiogenic therapy inhibits venous thrombus resolution. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34(3), 565-70.
Saha P, Andia ME, Modarai B, Blume U, Humphries J, Patel AS, Phinikaridou A, Evans CE, Mattock K, Grover S, Ahmad A, Lyons O, Attia RQ, Renne T, Premaratne S, Wiethoff AJ, Botnar RM, Schaeffter T, Waltham M, Smith A. Magnetic resonance T1 relaxation time of venous thrombus is determined by iron processing and predicts susceptibility to lysis. Circulation, 2013, 128, 729-36.
Kim J, Evans C, Weidemann A, Takeda N, Stockmann C, Branco-Price C, Branberg F, Leone G, Ostrowski M, Werb Z, Johnson RS. Loss of fibroblast HIF-1α accelerates tumorigenesis. Cancer Research, 2012, 72(13), 3187-95.
Branco-Price C, Zhang N, Schnelle M, Evans CE, Katchinsky DM, Liao D, Ellies L, Johnson RS. Endothelial cell HIF-1α and HIF-2α differentially regulate metastatic success. Cancer Cell, 2012, 21(1), 52-65.
Evans CE, Mattock K, Humphries J, Saha P, Ahmad A, Waltham M, Patel A, Modarai B, Porter L, Premaratne S, Smith A. Techniques of assessing hypoxia at the bench and bedside. Angiogenesis, 2011, 14(2), 119-24.
Evans CE, Humphries J, Mattock K, Waltham M, Wadoodi A, Saha P, Modarai B, Maxwell P, Smith A. Hypoxia and upregulation of hypoxia-inducible factor 1 alpha stimulate venous thrombus recanalisation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2443-51.
Pula G, Mayr U, Evans CE, Prokopi M, Yin X, Astroulakis Z, Xiao Q, Hill J, Xu Q, Mayr M. Proteomics identifies thymidine phosphorylase as a key regulator of the angiogenic potential of colony-forming units and endothelial progenitor cell cultures. Circulation Research, 2009, 104, 32-40.
For extended list please see following link to Pubmed.